Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
Aleksandra Kusowska, Matylda Kubacz, Marta Krawczyk, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1501-1501
Open Access | Times Cited: 17

Showing 17 citing articles:

Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation
Hadeer Mohamed Ahmed, Said S. Moselhy, Magda I. Mohamad, et al.
Annals of Hematology (2025)
Open Access | Times Cited: 1
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy
Aspasia Koudouna, Annita Ioanna Gkioka, Alexandros Gkiokas, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2862-2862
Open Access | Times Cited: 4
A Systematic Review Assessing the Impact of Vitamin D Levels on Adult Patients with Lymphoid Malignancies
Cristina Potre, Ema Borsi, Ovidiu Potre, et al.
Current Oncology (2023) Vol. 30, Iss. 4, pp. 4351-4364
Open Access | Times Cited: 8
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Juan José Mata, Joseba Rebollo-Liceaga, Elena Ma Martínez-Navarro, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Rituximab Resistance in Glomerular Diseases: A GlomCon Mini-Review
Tania Salehi, Anoushka Krishnan, Ayman Al Jurdi, et al.
Kidney Medicine (2024) Vol. 6, Iss. 4, pp. 100791-100791
Open Access | Times Cited: 2
Serum Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy
Marie‐Christine Kyrtsonis, Aspasia Koudouna, Annita Ioanna Gkioka, et al.
(2024)
Open Access | Times Cited: 1
Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking
Qiuling Zhao, Shengqiang Huang, Lin Yang, et al.
Technology and Health Care (2024) Vol. 32, Iss. 4, pp. 2091-2105
Closed Access | Times Cited: 1
In Vitro Diffuse Large B-Cell Lymphoma Cell Line Models as Tools to Investigate Novel Immunotherapeutic Strategies
Matylda Kubacz, Aleksandra Kusowska, Magdalena Winiarska, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 235-235
Open Access | Times Cited: 6
Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma
Dereje Mengesha Berta, Mekonnen Girma, Mulugeta Melku, et al.
International Journal of General Medicine (2023) Vol. Volume 16, pp. 2469-2480
Open Access | Times Cited: 2
Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Yanbing Li, Huijie Zhou, Liqun Zou
International Journal of Clinical Practice (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 3
Dynamic hydrogen peroxide levels reveal a rate-dependent sensitivity in B-cell lymphoma signaling
Melde Witmond, Emma Keizer, Bas Kiffen, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Development of a targeted IL-12 immunotherapy platform for B-cell lymphomas
Dahea Lee, Dongsu Kim, Donggeon Kim, et al.
International Immunopharmacology (2024) Vol. 139, pp. 112600-112600
Open Access
Underappreciated layers of antibody-mediated immune synapse architecture and dynamics
Benjamin S. Goldberg, Margaret E. Ackerman
mBio (2024)
Open Access
Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy
Ana Victoria Casadesús, Beatriz María Cruz, Wilden Díaz, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 2
Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
Bruno Brando, Arianna Gatti
Elsevier eBooks (2023), pp. 347-374
Closed Access
Therapeutic options for rituximab-resistant patients
Jing Wang, Ran Qin, Yanling Jin, et al.
Elsevier eBooks (2023), pp. 211-230
Closed Access
Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics
Tien Le, Erica Kim, Tracy Togba-Bass, et al.
Current Cancer Therapy Reviews (2022) Vol. 19, Iss. 2, pp. 84-95
Closed Access
Page 1

Scroll to top